How B12 reduces GLP-1 nausea at the molecular level Nausea affects up to 50% of patients taking GLP-1 receptor agonists
The trial, which began in October 2018, was originally designed to test the hypothesis that semaglutide could protect nondiabetic patients with metabolic syndrome, a condition characterized by excess body fat and insulin resistance, from cardiovascular events
Additionally, GTPs in the concentration of 500 and 1,000 mg significantly increased the excretion of AFB1mercapturic acid, the metabolized by-product of AFB1-8,9-epoxide, into urine which indicated a significant modification in the activity of GSTs (408)
Because it engages all three targets, it serves as a reference tool for research distinguishing triple-pathway activation from the dual GIP/GLP-1 mechanism characteristic of earlier-generation incretin compounds